Susquehanna International Group’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-51,090
| Closed | -$230K | – | 14095 |
|
|
2025
Q2 | $230K | Sell |
51,090
-9,570
| -16% | -$43K | ﹤0.01% | 10918 |
|
|
2025
Q1 | $269K | Buy |
60,660
+32,171
| +113% | +$187K | ﹤0.01% | 10305 |
|
|
2024
Q4 | $223K | Buy |
+28,489
| New | +$347K | ﹤0.01% | 10476 |
|
|
2024
Q2 | – | Sell |
-22,415
| Closed | -$364K | – | 13391 |
|
|
2024
Q1 | $364K | Buy |
22,415
+5,775
| +35% | +$77.8K | ﹤0.01% | 9253 |
|
|
2023
Q4 | $113K | Sell |
16,640
-6,070
| -27% | -$35.1K | ﹤0.01% | 11224 |
|
|
2023
Q3 | $124K | Sell |
22,710
-26,309
| -54% | -$153K | ﹤0.01% | 10740 |
|
|
2023
Q2 | $333K | Buy |
49,019
+186
| +0.4% | +$1.39K | ﹤0.01% | 9225 |
|
|
2023
Q1 | $245K | Buy |
48,833
+14,199
| +41% | +$58K | ﹤0.01% | 10171 |
|
|
2022
Q4 | $169K | Sell |
34,634
-4,034
| -10% | -$29.3K | ﹤0.01% | 10356 |
|
|
2022
Q3 | $558K | Buy |
38,668
+17,042
| +79% | +$282K | ﹤0.01% | 8198 |
|
|
2022
Q2 | $327K | Sell |
21,626
-12,791
| -37% | -$149K | ﹤0.01% | 9355 |
|
|
2022
Q1 | $409K | Buy |
34,417
+4,137
| +14% | +$42.5K | ﹤0.01% | 9486 |
|
|
2021
Q4 | $491K | Buy |
30,280
+3,701
| +14% | +$79.1K | ﹤0.01% | 9266 |
|
|
2021
Q3 | $759K | Buy |
26,579
+10,632
| +67% | +$335K | ﹤0.01% | 8280 |
|
|
2021
Q2 | $539K | Sell |
15,947
-3,379
| -17% | -$108K | ﹤0.01% | 9405 |
|
|
2021
Q1 | $584K | Buy |
19,326
+12,511
| +184% | +$513K | ﹤0.01% | 9126 |
|
|
2020
Q4 | $337K | Buy |
6,815
+1,501
| +28% | +$69.4K | ﹤0.01% | 9052 |
|
|
2020
Q3 | $204K | Sell |
5,314
-63
| -1% | -$2.51K | ﹤0.01% | 9419 |
|
|
2020
Q2 | $232K | Sell |
5,377
-7,253
| -57% | -$274K | ﹤0.01% | 8791 |
|
|
2020
Q1 | $330K | Buy |
+12,630
| New | +$367K | ﹤0.01% | 7796 |
|
|
2019
Q4 | – | Sell |
-8,974
| Closed | -$234K | – | 10796 |
|
|
2019
Q3 | $234K | Buy |
+8,974
| New | +$229K | ﹤0.01% | 8803 |
|
Other funds holding YMAB
Susquehanna International Group's YMAB Position: Q3 2025 in Review
Susquehanna International Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 51,090 shares — an estimated $230K sold.
Susquehanna International Group first reported a position in YMAB in Q3 2019 and held it in 21 quarters. The position peaked at $759K in Q3 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Susquehanna International Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 51,090 Y-mAbs Therapeutics shares in Q3 2025, an estimated $230K.
- Susquehanna International Group first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 21 quarters.
- Susquehanna International Group's Y-mAbs Therapeutics position peaked at $759K in Q3 2021.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.